Quote: "AdAlta conducted a study of AD-214 administered intravenously at various doses and dose intervals in the bleomycin mouse model. Treatment with AD-214 at 1-30mg/kg every second day and 10-30mg/kg every fourth day resulted in a statistically significant reduction in the Ashcroft Score of bleomycin-treated mice compared with mice receiving bleomycin alone (Figure 1). In contrast, treatment with two drugs currently approved for IPF – pirfenidone and nintedanib – did not result in a statistically significant reduction in Ashcroft score under test conditions."
Looks like we have a clear winner here. Bring on the human trials.
1AD Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)